Protein kinases, their function and implication in cancer and other diseases.

Protein phosphorylation is known to play an important role in various cellular processes such as cell division, metabolism, survival and apoptosis. It is driven by specific enzymes, tyrosine and serine-threonine protein kinases. Human protein kinases constitute a complicated system with intricate internal and external interactions. The complexity and sophistication of the system implies its vulnerability. Alterations in functions of these enzymes may launch series of pathological changes within the cell and as a result cause diseases. Protein kinases have been shown to be involved in various pathological processes, first of all malignancies. Deregulation of different protein kinases has been found in chronic myelogenous leukaemia, gastrointestinal stromal tumours, various other sarcomas and cancers as well as non-malignant disorders. Therefore, they are regarded as important effectors in human pathology and represent prospective therapeutic targets.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  K. Kaibuchi,et al.  Identification of Tau and MAP2 as novel substrates of Rho‐kinase and myosin phosphatase , 2003, Journal of neurochemistry.

[3]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[4]  L. Schang,et al.  Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. , 2004, Biochimica et biophysica acta.

[5]  L. Rönnstrand,et al.  Identification of Tyr-703 and Tyr-936 as the primary association sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor. , 1999, The Biochemical journal.

[6]  J. Boylan,et al.  Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. , 2004, Gene.

[7]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[8]  M. Tartaglia,et al.  Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. , 2006, Oncogene.

[9]  Peter Carmeliet,et al.  Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.

[10]  Haiwei Song,et al.  Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. , 2002, Pharmacology & therapeutics.

[11]  P. Fischer,et al.  Progress in the discovery of polo-like kinase inhibitors. , 2005, Current topics in medicinal chemistry.

[12]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[13]  H. Lenz,et al.  Epidermal growth factor receptor as a target for chemotherapy. , 2005, Clinical colorectal cancer.

[14]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[15]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[16]  F. Barlesi,et al.  Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective , 2005, Fundamental & clinical pharmacology.

[17]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[18]  Shengjun Ren,et al.  Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit , 2004, Cell.

[19]  S. Sartore,et al.  Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. , 1994, Clinical science.

[20]  M. Los,et al.  Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets. , 2005, Archivum immunologiae et therapiae experimentalis.

[21]  M. Dewji.  Early Phase I Data on an Irreversible Pan-Er Inhibitor: CI-1033. What Did We Learn? , 2004, Journal of chemotherapy.

[22]  X. Q. Chen,et al.  The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton , 1996, Molecular and cellular biology.

[23]  K. Araki,et al.  STI571 (Glivec) inhibits the interaction between c‐KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST‐T1 , 2005, Cancer science.

[24]  A. Jones,et al.  Oncogenic protein tyrosine kinases , 2004, Cellular and Molecular Life Sciences CMLS.

[25]  Patricia L. Harris,et al.  Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Nguyen,et al.  Protein kinases expressed by interstitial cells of Cajal , 2003, Histochemistry and Cell Biology.

[27]  G. D. Guetz,et al.  Treatment of Gastrointestinal Stromal Tumors with Imatinib Mesylate:A Major Breakthrough in the Understanding of Tumor-specific Molecular Characteristics , 2005, World Journal of Surgery.

[28]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[29]  Michael B Yaffe,et al.  Structure and function of Polo-like kinases , 2005, Oncogene.

[30]  Y. Sánchez,et al.  Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. , 2000, Cancer research.

[31]  Helmut Mack,et al.  Rho kinase, a promising drug target for neurological disorders , 2005, Nature Reviews Drug Discovery.

[32]  E. Russell.  Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[33]  A. Altman,et al.  Protein kinase C-theta mediates a selective T cell survival signal via phosphorylation of BAD. , 2001, Journal of immunology.

[34]  J. Fletcher,et al.  Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). , 2004, Cancer research.

[35]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.

[36]  Toshikazu Nakamura,et al.  Specific Activation of LIM kinase 2 via Phosphorylation of Threonine 505 by ROCK, a Rho-dependent Protein Kinase* , 2001, The Journal of Biological Chemistry.

[37]  J. O’Shea,et al.  JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. , 2004, Trends in molecular medicine.

[38]  Shailendra Giri,et al.  Rho/ROCK pathway as a target of tumor therapy , 2006, Journal of neuroscience research.

[39]  F. Lo‐Coco,et al.  8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes , 2005, Genes, chromosomes & cancer.

[40]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[41]  K. Nocka,et al.  Molecular bases of dominant negative and loss of function mutations at the murine c‐kit/white spotting locus: W37, Wv, W41 and W. , 1990, The EMBO journal.

[42]  A. Koleske,et al.  Bidirectional Signaling Links the Abelson Kinases to the Platelet-Derived Growth Factor Receptor , 2004, Molecular and Cellular Biology.

[43]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[44]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[45]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[46]  H. Kawai,et al.  Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis , 2005, Oncogene.

[47]  P. Furet,et al.  4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. , 1996, Journal of medicinal chemistry.

[48]  C. Antonescu,et al.  Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[50]  有村 奈利子.  Phosphorylation of collapsin response mediator protein-2 by Rho-kinase : evidence for two separate signaling pathways for growth cone collapse , 2003 .

[51]  R. Flavell,et al.  Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. , 1998, Immunity.

[52]  D. Morrison,et al.  Cancer: Enzymes play molecular tag , 2004, Nature.

[53]  A. Rosenwald,et al.  Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms , 2005, Leukemia.

[54]  J. Fletcher,et al.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) , 2004, Oncogene.

[55]  K. Nakao,et al.  ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice , 1996, FEBS letters.

[56]  G. Cheetham.  Novel protein kinases and molecular mechanisms of autoinhibition. , 2004, Current opinion in structural biology.

[57]  D. Fabbro,et al.  SRC family kinases: potential targets for the treatment of human cancer and leukemia. , 2003, Current pharmaceutical design.

[58]  Double target for tumor mass destruction. , 2003, The Journal of clinical investigation.

[59]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  I. Ceccherini,et al.  Molecular mechanisms of RET‐induced Hirschsprung pathogenesis , 2006, Annals of medicine.

[61]  A. Tolcher,et al.  Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. , 2003, Seminars in oncology.

[62]  W. Leonard.  Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. , 1996, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[63]  J. Liu,et al.  Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metazoa. , 2000, Molecular biology and evolution.

[64]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[65]  P. Schaffer,et al.  Explant-Induced Reactivation of Herpes Simplex Virus Occurs in Neurons Expressing Nuclear cdk2 and cdk4 , 2002, Journal of Virology.

[66]  R. V. van Etten,et al.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.

[67]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[68]  R. V. van Etten,et al.  Cycling, stressed-out and nervous: cellular functions of c-Abl. , 1999, Trends in cell biology.

[69]  T. Herdegen,et al.  Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. , 2005, Trends in pharmacological sciences.

[70]  M. Lacouture,et al.  The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. , 2005, Journal of the American Academy of Dermatology.

[71]  M. Tatsuta,et al.  Bile reflux: a possible cause of stomach ulcer in nontreated mutant mice of W/WV genotype. , 1982, Gastroenterology.

[72]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[73]  Stephen S. Taylor,et al.  Aneuploid colon cancer cells have a robust spindle checkpoint , 2001, EMBO reports.

[74]  P. Rakic,et al.  The Jnk1 and Jnk2 Protein Kinases Are Required for Regional Specific Apoptosis during Early Brain Development , 1999, Neuron.

[75]  S. Narumiya,et al.  Targeted Disruption of the Mouse Rho-Associated Kinase 2 Gene Results in Intrauterine Growth Retardation and Fetal Death , 2003, Molecular and Cellular Biology.

[76]  F. Uckun,et al.  Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. , 2004, Current pharmaceutical design.

[77]  Christopher J. Wilkinson,et al.  The Polo kinase Plk4 functions in centriole duplication , 2005, Nature Cell Biology.

[78]  P. Collins,et al.  Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation‐contraction coupling , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  A. Ullrich,et al.  Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.

[80]  D. Vance,et al.  Phosphorylation of Sp1 by Cyclin-dependent Kinase 2 Modulates the Role of Sp1 in CTP:Phosphocholine Cytidylyltransferase α Regulation during the S Phase of the Cell Cycle* , 2004, Journal of Biological Chemistry.

[81]  Pascal Furet,et al.  Tyrosine kinase inhibitors: From rational design to clinical trials , 2001, Medicinal research reviews.

[82]  P. Wen,et al.  Targeted molecular therapy of malignant gliomas , 2005, Current oncology reports.

[83]  R. Salgia,et al.  Targeting c-Kit mutations: basic science to novel therapies. , 2004, Leukemia research.

[84]  M. J. Davis,et al.  Regulation of ion channels by protein tyrosine phosphorylation. , 2001, American journal of physiology. Heart and circulatory physiology.

[85]  F. Galibert,et al.  Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4 , 1988, Human Genetics.

[86]  Michael Karin,et al.  A central role for JNK in obesity and insulin resistance , 2002, Nature.

[87]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[88]  P. Pacaud,et al.  Rho kinases in cardiovascular physiology and pathophysiology. , 2006, Circulation research.

[89]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[90]  T. Herdegen,et al.  c-Jun N-Terminal Protein Kinase (JNK) 2/3 Is Specifically Activated by Stress, Mediating c-Jun Activation, in the Presence of Constitutive JNK1 Activity in Cerebellar Neurons , 2002, The Journal of Neuroscience.

[91]  D. Baltimore,et al.  Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. , 1992, Science.

[92]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[93]  N. Pavletich,et al.  Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. , 1998, Molecular biology of the cell.

[94]  M. Tatsuta,et al.  Spontaneous stomach ulcer in genetically mast-cell depleted W/Wv mice , 1980, Nature.

[95]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[96]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[97]  A. Ullrich,et al.  Interaction of the receptor tyrosine kinase p145c‐kit with the p210bcr/abl kinase in myeloid cells , 1996, British journal of haematology.

[98]  T. Fehm,et al.  Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. , 2004, Anticancer research.

[99]  R. Engh,et al.  Structural aspects of protein kinase control-role of conformational flexibility. , 2002, Pharmacology & therapeutics.

[100]  R. Ross,et al.  Growth Regulatory Mechanisms and Formation of the Lesions of Atherosclerosis a , 1994, Annals of the New York Academy of Sciences.

[101]  D. Gordon.  Growth factors and cell proliferation in human transplant arteriosclerosis. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[102]  G. Breier,et al.  The role of vascular endothelial growth factor in blood vessel formation. , 1996, Trends in cell biology.

[103]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[104]  Dr Tessa L. Holyoake.  Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory , 2001, British journal of haematology.

[105]  Y. Sánchez,et al.  Chk1 in the DNA damage response: conserved roles from yeasts to mammals. , 2004, DNA repair.

[106]  D. Housman,et al.  The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene , 1988, Cell.

[107]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[108]  E. Sausville.  Complexities in the development of cyclin-dependent kinase inhibitor drugs. , 2002, Trends in molecular medicine.

[109]  D. Birnbaum,et al.  Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. , 1991, Oncogene.

[110]  M. Deininger.  Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia , 2004, Journal of Cancer Research and Clinical Oncology.

[111]  Mark Ellisman,et al.  JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. , 2003, Developmental cell.

[112]  H. Dohlman,et al.  MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. , 2005, Current opinion in chemical biology.

[113]  J. Verweij.  KIT and PDGF as targets. , 2004, Cancer treatment and research.

[114]  J. D. Di Santo,et al.  The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. , 2000, Blood.

[115]  G. Daley,et al.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[116]  S. Eckhardt,et al.  Tyrosine kinase inhibitors in cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[117]  Y. Kitamura,et al.  Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. , 1978, Blood.

[118]  S. Hirota,et al.  Gastrointestinal stromal tumors (GIST): A model for molecule‐based diagnosis and treatment of solid tumors , 2003, Cancer science.

[119]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[120]  M. Caligiuri,et al.  Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[121]  S. Nishikawa,et al.  Requirement of c-kit for development of intestinal pacemaker system. , 1992, Development.

[122]  M. Winey,et al.  A Field Guide to the Mps1 Family of Protein Kinases , 2004, Cell cycle.

[123]  L. Schang.  Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. , 2005, Current drug targets. Infectious disorders.

[124]  K. Shokat,et al.  Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[125]  O. Witte,et al.  The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc , 1989, Molecular and cellular biology.

[126]  J. D. de Bono,et al.  Drugging cell cycle kinases in cancer therapy. , 2005, Current drug targets.

[127]  W. Schwaiger,et al.  Relevance of Atypical Protein Kinase C Isotypes to the Drug Discovery Process , 2005, Chembiochem : a European journal of chemical biology.

[128]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[129]  J. Raizer.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme , 2005, Journal of Neuro-Oncology.

[130]  E. Kebebew,et al.  Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[131]  D. Burke,et al.  The spindle assembly and spindle position checkpoints. , 2003, Annual review of genetics.

[132]  Stevan R. Hubbard,et al.  Juxtamembrane autoinhibition in receptor tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[133]  A. Pendergast.  The Abl family kinases: mechanisms of regulation and signaling. , 2002, Advances in cancer research.

[134]  I. Mcniece,et al.  Stem cell factor. , 1995, Journal of leukocyte biology.

[135]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[136]  L. Berg,et al.  Peripheral Expression of Jak3 Is Required to Maintain T Lymphocyte Function , 1997, The Journal of experimental medicine.